ライフサイエンスコーパス: body weight gain

1 acid concentrations and reduces the rate of body weight gain.

2 factor-I, IGF binding protein-3, leptin, or body weight gain.

3 , less time attached to the nipple, and less body weight gain.

4 n any animal and did not suppress group mean body weight gain.

5 Neither genistein nor soy products reduced body weight gain.

6 EA used induced no toxicity or alteration in body weight gain.

7 mpanied by an increase in food intake and in body weight gain.

8 te physical activity, which in turn prevents body weight gain.

9 lso prevented the amylin-induced decrease of body weight gain.

10 type VMH significantly increases feeding and body weight gain.

11 y lost, resulting in rapid WAT expansion and body weight gain.

12 ntagonist, significantly reduced the rate of body weight gain.

13 ipulation can result in a robust and chronic body weight gain.

14 icantly decreased food and water intake, and body weight gain.

15 w without alterations in rearing behavior or body weight gain.

16 ciency, such as reduced food intake and poor body weight gain.

17 n and glucose concentrations associated with body weight gain.

18 normoglycemic over 60 days, and had reduced body weight gain.

19 -161503 decreased food intake and attenuated body weight gain.

20 and lipids in animal models without causing body weight gain.

21 inhibited jejunal contraction, and decreased body-weight gain.

22 otype with reduced microglial activation and body-weight gain.

23 ted commercial vaccines, with no decrease in body weight gains.

24 ient to decrease pup mortalilty, to increase body weight gain (+0.1 g/day) and to delay the onset of

25 del of high-fat diet-induced obesity reduced body weight gain, adiposity and insulin resistance.

26 ned by adrenal gland weight, and verified by body weight gain after repeated restraint stress, and fe

27 normalize energy intake and showed increased body weight gain after the HFD challenge.

28 ws prediction of ROP risk based on postnatal body weight gain alone.

29 R2 blockade in ob/ob mice leads to a reduced body-weight gain, an improvement in insulin sensitivity,

30 Body weight gain and adipose tissue mass were significan

31 Food intake, body weight gain and adiposity were greater for rats tha

32 neal administration of LEP-(116-130) reduced body weight gain and blood glucose levels but not food i

33 t diet for 10 weeks, CCK-KO mice had reduced body weight gain and body fat mass and enlarged adipocyt

34 Surviving animals resumed normal body weight gain and clinical performance within 5 days

35 an improved metabolic phenotype with reduced body weight gain and enhanced glucose tolerance by induc

36 rhythms in temperature, locomotor activity, body weight gain and food intake and adipose depot weigh

37 Subsequently, body weight gain and food intake increased and caloric e

38 in-expressing astrocytes induced exaggerated body weight gain and glucose intolerance in mice exposed

39 o overexpression of G3PP in rat liver lowers body weight gain and hepatic glucose production from gly

40 al white adipose tissue, with an increase in body weight gain and impaired insulin signaling.

41 VSL#3 suppressed body weight gain and insulin resistance via modulation o

42 (-/-)) mice were protected from HFD-enhanced body weight gain and insulin resistance.

43 n was assessed 6 days after challenge, using body weight gain and intestinal lesion scores.

44 their pharmacological stabilization, reduces body weight gain and levels of inflammatory cytokines, c

45 ct of LA was associated with almost 40% less body weight gain and lower serum and very low-density li

46 ese angiogenesis-targeted NPs have inhibited body weight gain and modulated several serological marke

47 atory ratio controlled inflammation, reduced body weight gain and protected from hyperglycemia on hig

48 d progression of motor dysfunction, improved body weight gain and survival with the amelioration of n

49 esistance or high insulin secretion promotes body weight gain and the development of insulin resistan

50 to attenuate the L-CPA-induced reductions in body weight gain and the prevention of the loss in hindl

51 Subchronic treatment with OEA reduced body weight gain and triacylglycerol content in liver an

52 ion of resveratrol (10 ppm) had no effect on body weight gain and tumor volume but produced striking

53 n rats, 5 days of amylin treatment decreased body weight gain and/or food intake and increased IL-6 m

54 te concentration and alleviated diet-induced body-weight gain and adiposity in mice.

55 The high-fat diet increased body-weight gain and plasma leptin levels.

56 ranosyl cytidine (AraC) blunted food intake, body weight gain, and adiposity.

57 on of Rb1 significantly reduced food intake, body weight gain, and body fat content and increased ene

58 We detected improved sleep, prevention of body weight gain, and deceleration of cardiac aging unde

59 (MBH) reduces food intake, protects against body weight gain, and limits adiposity, suggesting that

60 hyperphagia of these mice led to accelerated body weight gain as compared with otherwise matched cont

61 was paralleled by decreased food intake and body weight gain as well as increased energy expenditure

62 CSEE caused dose-related reductions in body weight gain (as well as plasma lipid levels and epi

63 rains in the gut (~5 logs) and increased the body-weight-gain at 4-5 weeks of age compared to non-RB

64 ic-exposed females had significantly greater body weight gain, body fat content, and glucose intolera

65 This treatment attenuated HFD-induced body weight gain, body fat mass accumulation, increased

66 ss sensitive than APOE3 mice to diet-induced body weight gain but exhibited hyperinsulinemia, and the

67 oleoylethanolamide (OEA) reduces feeding and body weight gain by activating the nuclear receptor PPAR

68 stent spatial memory deficits, and decreased body weight gain compared to experimental counterparts a

69 se early body weight gain while holding late body weight gain constant; E-LO was selected to decrease

70 C57BL/6 pups exhibited prolonged deficits in body weight gain (days 12-30) compared with BALB/c pups

71 interesting therapeutic approach to prevent body weight gain, decrease fat mass, and improve insulin

72 ion results in modulation of food intake and body weight gain, demonstrating significant therapeutic

73 Body weight gain did not differ between wild-type (WT) a

74 bH null mice displayed significantly reduced body-weight gain, diminished abdominal fat, and increase

75 consumption was not associated with greater body weight gain during 8 y of follow-up in healthy midd

76 Maternal body weight gain during gestation averaged 282 and 57 g

77 lts confirm the location for body weight and body weight gain during growth that were identified in p

78 ure had no effect on survival but did affect body weight gain during treatment.

79 16 globally have low birth weight, increased body weight gain, energy expenditure and hyperphagia.

80 consequences of hypercaloric diet, including body weight gain, energy expenditure, and fatty acid oxi

81 h- and low-calorie chips exhibited increased body weight gain, food intake and adiposity when they we

82 hese effects were associated with attenuated body weight gain, food intake and improved physiological

83 f central PPARgamma promotes food intake and body weight gain; however, the identity of the neurons t

84 TRF prevents excessive body weight gain, improves sleep, and attenuates age- an

85 NGF suppressed the body weight gain in 4MO rats but did not affect 23MO rat

86 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

87 component of energy homeostasis that alters body weight gain in a gender-specific fashion.

88 tration of 33A did not affect food intake or body weight gain in a mouse model of diet-induced obesit

89 atment groups; however, naltrexone decreased body weight gain in both lactating and post-lactating su

90 increased cumulative food intake and overall body weight gain in controls but they increased subcutan

91 L-NAME significantly reduced body weight gain in DIO but not in chow-fed rats.

92 g the persistent low birth weight, increased body weight gain in early adulthood, increased energy ex

93 is associated with increased food intake and body weight gain in female rats; to evaluate whether thi

94 The decreased body weight gain in GPRKO female mice is due to the redu

95 lucose tolerance and reduces food intake and body weight gain in healthy, obese and diabetic rats.

96 sociated with a reduction of food intake and body weight gain in normal and obese animals.

97 Food intake and body weight gain in other rats with partial lesions of t

98 ogical levels of insulin are associated with body weight gain in patients.

99 The decrease body weight gain in PTL(-/-) and PTL(-/-), CEL(-/-) mice

100 se-dependently suppress food consumption and body weight gain in rats following single intraperitonea

101 RNA resulted in hyperphagia and exacerbated body weight gain in rats maintained on high-fat diet.

102 th high GC concentrations, usually decreases body weight gain in rats; by contrast, in stressed or de

103 ses feed efficiency, relative adiposity, and body weight gain in relation to the immune response elic

104 ypothalamus, potently stimulates feeding and body weight gain in rodents.

105 h control IgG but also significantly reduced body weight gain in the pups, suggesting an adverse effe

106 or fluid intake, physical activity levels or body weight gain in the rat, whereas it depleted muscle

107 ay dose, there was a significant decrease in body weight gain in the rats.

108 in the absence of any significant effect on body weight gain in the treated rats.

109 stration of OEA produces satiety and reduces body weight gain in wild-type mice, but not in mice defi

110 altered food intake, energy expenditure, and body weight gain in WT mice, FGF21-deficient animals did

111 de hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been h

112 4 microinjection to suppress food intake and body weight gain; in contrast, intracore NMDA receptor b

113 Alcohol intake prevented body weight gain, induced the formation of uncoupling pr

114 rotein content 23.9%) increased food intake, body weight gain, lean body mass, and gastrocnemius musc

115 After birth they are characterized by low body weight gain, marked hypotension, and abnormal kidne

116 CD40 deficiency (CD40KO) resulted in greater body weight gain, more severe inflammation in epididymal

117 -I or both resulted in significantly greater body weight gain, nitrogen retention, and serum total IG

118 On average, the body weight gain of 3NOP-treated cows was 80% greater th

119 Furthermore, the reduced body weight gain of the mutant mice was largely due to t

120 emonstrate that TPL2 deletion does not alter body weight gain or adipose depot weight.

121 ces either increased comfort food intake and body weight gain or decreased intake and body weight los

122 pletion, there was no effect on food intake, body weight gain, or total carcass adiposity on chow or

123 E4, animals with dietary n-3 PUFAs decreased body-weight gain, plasma lipids, and insulin (P < 0.05)

124 -bearing rats were accompanied by attenuated body weight gain post-LPS.

125 y 9 was found to be effective in suppressing body weight gain relative to control in a diet-induced o

126 associated with a significant retardation of body weight gain shortly after sulfone administration an

127 induced diabetes results in normalization of body weight gain, significant control of hyperglycemia a

128 d without overt clinical disease, but showed body weight gains significantly reduced by 6.5-11.4% beg

129 d to OSPM exhibited significant decreases in body weight gain, systemic oxidative stress in the form

130 t diet, the IAP-deficient mice showed faster body weight gain than did control animals.

131 gnificantly lower oocyst shedding and normal body weight gain than nonvaccinated and infected control

132 the MeA of adult male mice produced a rapid body weight gain that was associated with remarkable red

133 etabolic changes were sufficient to increase body weight gain under normal chow feeding and exacerbat

134 tained reduction in blood glucose levels and body weight gains up to 5-7 days, whereas the efficacy o

135 However, body weight gain was 6.2 and 8.6 g less (p < 0.01) in PT

136 Body weight gain was accelerated in rAAV-GFP + HFD contr

137 ese findings and demonstrated that increased body weight gain was also demonstrated when animals cons

138 Body weight gain was not significantly different among g

139 A reduction in body weight gain was observed in ApoE(-/-) mice fed a hi

140 Increases in body mass index and percentage body weight gain were also significantly lower in women

141 ays posthatch, and fecal-oocyst shedding and body weight gain were determined as parameters of coccid

142 Daily food consumption and body weight gain were not affected.

143 Mean body weight gains were not significantly different betwe

144 k physiological mechanisms to defend against body weight gain when food is abundant.

145 minal fat independent of caloric content and body weight gain, whereas increasing meal size did not.

146 follows; E+LO was selected to increase early body weight gain while holding late body weight gain con

147 f diet-dependent microglia expansion hinders body weight gain while preventing central and peripheral

148 administration of 11 reduced food intake and body weight gain without causing CNS-related malaise.

149 gh-producing dairy cows by 30% and increased body weight gain without negatively affecting feed intak

150 Minimal intermittent stimulation led to body weight gain; ZI GABA neuron ablation reduced weight